These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 2147819

  • 21. Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen.
    Sobbrio GA, Granata A, Granese D, D'Arrigo F, Panacea A, Nicita R, Pullè C, Trimarchi F.
    Clin Exp Obstet Gynecol; 1991; 18(1):43-5. PubMed ID: 1829029
    [Abstract] [Full Text] [Related]

  • 22. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
    Chez RA.
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive.
    Täuber U, Kuhnz W, Hümpel M.
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 2):1414-20. PubMed ID: 2220966
    [Abstract] [Full Text] [Related]

  • 24. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 150 micrograms desogestrel.
    Kuhl H, Jung-Hoffmann C, Heidt F.
    Contraception; 1988 Sep; 38(3):381-90. PubMed ID: 2971509
    [Abstract] [Full Text] [Related]

  • 25. Blood coagulation with a combination pill containing gestodene and ethinyl estradiol.
    Bonnar J, Daly L, Carroll E.
    Int J Fertil; 1987 Sep; 32 Suppl():21-8. PubMed ID: 2906344
    [Abstract] [Full Text] [Related]

  • 26. Serum concentrations of ethinylestradiol, 3-keto-desogestrel, SHBG, CBG and gonadotropins during treatment with a biphasic oral contraceptive containing desogestrel.
    Jung-Hoffmann C, Storch A, Kuhl H.
    Horm Res; 1992 Sep; 38(3-4):184-9. PubMed ID: 1306851
    [Abstract] [Full Text] [Related]

  • 27. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B.
    Ann Pharmacother; 1995 Sep; 29(7-8):736-42. PubMed ID: 8520092
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel.
    Orme M, Back DJ, Ward S, Green S.
    Contraception; 1991 Apr; 43(4):305-16. PubMed ID: 1830266
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings.
    Timmer CJ, Apter D, Voortman G.
    Contraception; 1990 Dec; 42(6):629-42. PubMed ID: 2150632
    [Abstract] [Full Text] [Related]

  • 31. Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives.
    Jung-Hoffmann C, Kuhl H.
    Contraception; 1989 Sep; 40(3):299-312. PubMed ID: 2527727
    [Abstract] [Full Text] [Related]

  • 32. New progestogens in oral contraceptives.
    Runnebaum B, Rabe T.
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
    [Abstract] [Full Text] [Related]

  • 33. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women.
    Petersen KR, Sidelmann J, Skouby SO, Jespersen J.
    Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):32-8. PubMed ID: 8420344
    [Abstract] [Full Text] [Related]

  • 34. Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: a one-year randomized, prospective, comparative trial.
    Jandrain BJ, Humblet DM, Jaminet CB, Scheen AJ, Gaspard UJ, Lefebvre PJ.
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):378-81. PubMed ID: 2142578
    [Abstract] [Full Text] [Related]

  • 35. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene.
    Kuhl H, Jung-Hoffmann C, Heidt F.
    Contraception; 1988 Oct; 38(4):477-86. PubMed ID: 3208516
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Prodrug versus drug effects of 150 micrograms desogestrel or 3-keto-desogestrel in combination with 30 micrograms ethinylestradiol on hormonal parameters: relevance of the peak serum level of 3-keto-desogestrel.
    Kuhl H, Jung-Hoffmann C, Fitzner M.
    Horm Res; 1995 Oct; 44(3):126-32. PubMed ID: 7590643
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance.
    Endrikat J, Jaques MA, Mayerhofer M, Pelissier C, Müller U, Düsterberg B.
    Contraception; 1995 Oct; 52(4):229-35. PubMed ID: 8605781
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.